|1.||Rivarola, Héctor W: 2 articles (06/2015 - 06/2007)|
|2.||Paglini-Oliva, Patricia: 2 articles (06/2015 - 06/2007)|
|3.||Chou, Janice Y: 2 articles (01/2009 - 12/2008)|
|4.||Pan, Chi-Jiunn: 2 articles (01/2009 - 12/2008)|
|5.||Lee, Soojung: 2 articles (01/2009 - 12/2008)|
|6.||Chen, Shih-Yin: 2 articles (01/2009 - 12/2008)|
|7.||Amador, Cristian: 1 article (07/2015)|
|8.||Farman, Nicolette: 1 article (07/2015)|
|9.||Latouche, Céline: 1 article (07/2015)|
|10.||Berger, Thorsten: 1 article (07/2015)|
01/21/2015 - "The PET/CT and ROI results showed high tumor uptake of (18)F-bivalent-IA in U-87 MG tumor-bearing mice from 5 to 120 min p.i. with good contrast, and the U-87 MG tumor uptake values (6.35 ± 0.67%ID/g, at 1 h p.i.) were 6 times higher than those of MDA-MB-231 tumor (1.05 ± 0.12%ID/g, at 1 h p.i.) (P < 0.0001) which correlated with the integrin αvβ3 expression in tumor tissues confirmed by immunohistochemistry. "
08/05/2013 - "(64)Cu-CBT2G showed significantly higher LNCaP tumor uptake than (64)Cu-CBT1G at 1, 4, and 24 h postinjection (p.i.) (p < 0.05). "
12/01/2008 - "Apart from higher tumor-to-liver ratios (17-fold, 1.5 h p.i.), both tumor-to-kidney and tumor-to-blood ratios could be significantly improved by a factor of 1.5 and 2.7, respectively (1.5 h p.i., P<0.05). "
01/01/1993 - "Previous studies demonstrated that an antisense phosphorothioate oligodeoxynucleotide, ISIS 3466, to the human nucleolar p120 protein, markedly inhibited the growth of human tumor cell lines in vitro and inhibited the growth of the human LOX tumor in vivo in an i.p./i.p. "
10/15/1993 - "Previous reports from this laboratory have shown marked cytocidal effects of the ISIS-3466 antisense phosphorothioate oligodeoxynucleotide to the human nucleolar protein p120 on human cancer cell lines in vitro and inhibition of tumor growth in vivo in an i.p/i.p. "
03/15/1987 - "In the initial studies with P388 leukemia (i.p.-i.p.), KW2152 gave an increase in life span of greater than 80%. "
01/01/1992 - "The 5FU-terminated PEG conjugates obtained exhibited significant survival effects against p388 leukemia mice i.p./i.p. "
04/01/1990 - "system) and P388 leukemia (i.p.-i.p. "
01/01/1989 - "In the initial studies with P388 leukemia (i.p.-i.p.), NC-190 led to an increase of greater than 200% in life span (ILS), and 75% of the mice were alive on day 30, when the optimal dose (50 mg/kg, days 1-5) was given. "
11/01/1987 - "In P388 leukemia (inoculated intraperitoneally (i.p.), administered i.p.: i.p.-i.p.) the maximal increase in life span (ILSmax) resulting from an administration of RA-700 (4 mg/kg/d for 9 d) was 134% and the therapeutic ratio was 400. "
05/01/1994 - "KW-2189 was also effective against murine P388 leukemia and L1210 leukemia not only by local administration (i.p.-i.p. "
03/15/1987 - "The order of in vitro efficacy of KW2152 against murine tumors, P388 leukemia greater than L1210 leukemia, B16 melanoma, correlated with the order of the sensitivity on the i.p.-i.p. "
02/01/1984 - "All prodrugs entrapped in liposome or O/W emulsion showed significant antitumor activities against L1210 leukemia in i.p.-i.p. "
|5.||Birth Weight (Birth Weights)
|6.||Collagen Type I (Type I Collagen)
|7.||Messenger RNA (mRNA)
|9.||Immunoglobulin G (IgG)
|10.||Transforming Growth Factor beta1 (TGF beta 1)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Patient Admission (Patient Admissions)